Edition:
United States

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

8.35USD
11:28am EDT
Change (% chg)

$-0.21 (-2.45%)
Prev Close
$8.56
Open
$8.60
Day's High
$8.60
Day's Low
$8.23
Volume
4,377
Avg. Vol
25,745
52-wk High
$9.25
52-wk Low
$3.70

GLYC.OQ

Chart for GLYC.OQ

About

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $193.29
Shares Outstanding(Mil.): 22.58
Dividend: --
Yield (%): --

Financials

  GLYC.OQ Industry Sector
P/E (TTM): -- 42.42 37.52
EPS (TTM): -0.73 -- --
ROI: -33.30 -9.34 14.48
ROE: -33.40 -9.70 15.65

BRIEF-Glycomimetics announces pricing of public offering

* Says public offering of 3.30 million common shares priced at $6.10 per share

Jun 17 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.85 -0.30
Novartis AG (NOVN.S) CHF81.90 -0.60
Pfizer Inc. (PFE.N) $36.74 -0.09
Merck & Co., Inc. (MRK.N) $58.34 -0.02
Roche Holding Ltd. (ROG.S) CHF249.30 -1.00
Roche Holding Ltd. (RO.S) CHF250.00 -1.25
Bayer AG (BAYGn.DE) €94.62 +1.05
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.